Company type | Public |
---|---|
| |
Industry | |
Founded | 1988 |
Founders | |
Headquarters | Tarrytown, New York, U.S. |
Area served | Global |
Key people | |
Revenue | US$13.12 billion (2023) |
US$4.05 billion (2023) | |
US$3.95 billion (2023) | |
Total assets | US$33.08 billion (2023) |
Total equity | US$25.97 billion (2023) |
Number of employees | 13,450 (2023) |
Website | www |
Footnotes / references [1] |
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.[2] Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.